Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 13/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 13/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 13/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 10/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 8/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 8/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5262452 | 0.85 | GABRA1 (0.50) | GABRA1GABRG2GABRB3GABRA2GABRA5 | |
| SCHEMBL5262983 | 0.72 | GABRA1 (0.53) | GABRA1GABRG2GABRB3GABRA2GABRA5 | |
| SCHEMBL6202841 | 0.72 | GABRA1 (0.50) | GABRA1GABRG2GABRB3GABRA2GABRA5 | |
| SCHEMBL6201966 | 0.72 | GABRA1 (0.50) | GABRA1GABRG2GABRB3GABRA2GABRA5 | |
| SCHEMBL5260164 | 0.71 | GABRA1 (0.41) | GABRA1GABRG2GABRB3GABRA2GABRA5 | |
| SCHEMBL6198921 | 0.70 | FYN (0.51) | GABRA1GABRG2GABRB3GABRA2GABRA5 | |
| SCHEMBL6200896 | 0.70 | GABRA1 (0.54) | GABRA1GABRG2GABRB3GABRA2GABRA5 | |
| SCHEMBL6202612 | 0.70 | GABRA1 (0.46) | GABRA1GABRG2GABRB3GABRA2GABRA5 | |
| SCHEMBL6200443 | 0.69 | SYK (0.48) | GABRA1GABRG2GABRB3GABRA2GABRA5 | |
| SCHEMBL6199865 | 0.69 | GABRA1 (0.54) | GABRA1GABRG2GABRB3GABRA2GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451161-B1 | IMIDAZOPYRIDINES, PYRIMIDINES AND TRIAZINES FOR ENHANCING COGNITION AS GABA-A ALPHA 5 RECEPTOR SUBTYPE LIGANDS | MERCK SHARP & DOHME (GB) | 2007-04-18 | — | — | EP | claimed |
| US-20060040940-A1 | Imidazopyridines pyrimidines and triazines for enhancing cognition as gaba-a-alphas 5 receoptor subtype ligands | BETTATI MICHELA | 2006-02-23 | — | — | US | claimed |
| EP-1451161-B1 | IMIDAZOPYRIDINES, PYRIMIDINES AND TRIAZINES FOR ENHANCING COGNITION AS GABA-A ALPHA 5 RECEPTOR SUBTYPE LIGANDS | MERCK SHARP & DOHME (GB) | 2007-04-18 | — | — | EP | disclosed |
| US-20060040940-A1 | Imidazopyridines pyrimidines and triazines for enhancing cognition as gaba-a-alphas 5 receoptor subtype ligands | BETTATI MICHELA | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040940-A1 | Imidazopyridines pyrimidines and triazines for enhancing cognition as gaba-a-alphas 5 receoptor subtype ligands | CHRNA3, GABRA3, GABRB3 | GABRA1 8/4885GABRG2 61/4885GABRB3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.